Theravance Biopharma (TBPH) Depreciation & Amortization (CF) (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $381000.0 in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 7.75% year-over-year to $381000.0 in Q1 2026; TTM through Mar 2026 was $1.6 million, a 5.74% decrease from a year earlier, with the FY2025 full-year figure at $1.6 million, down 4.91% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $381000.0, down from $399000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for TBPH reached as high as $1.1 million in Q3 2022 and fell as low as $381000.0 in Q1 2026.
• Historically, Depreciation & Amortization (CF) has averaged $554941.2 across 5 years, with a median of $429000.0 in 2024.
• Across the five-year window, Depreciation & Amortization (CF) jumped 162.55% in 2022 and plunged 61.01% in 2023, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $659000.0 in 2022, then sank by 40.52% to $392000.0 in 2023, then increased by 7.65% to $422000.0 in 2024, then fell by 5.45% to $399000.0 in 2025, then fell by 4.51% to $381000.0 in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $381000.0 in Q1 2026, $399000.0 in Q4 2025, and $405000.0 in Q3 2025.